S&P 500   3,901.82
DOW   31,535.51
QQQ   323.59
pixel
pixel
pixel
S&P 500   3,901.82
DOW   31,535.51
QQQ   323.59
pixel
pixel
pixel
S&P 500   3,901.82
DOW   31,535.51
QQQ   323.59
pixel
pixel
pixel
S&P 500   3,901.82
DOW   31,535.51
QQQ   323.59
pixel
pixel
pixel
Log in
NASDAQ:URGN

UroGen Pharma Stock Forecast, Price & News

$20.46
+1.41 (+7.40 %)
(As of 03/1/2021 12:00 AM ET)
Add
Compare
Today's Range
$19.50
Now: $20.46
$20.53
50-Day Range
$19.05
MA: $22.66
$26.96
52-Week Range
$13.12
Now: $20.46
$30.89
Volume238,522 shs
Average Volume183,369 shs
Market Capitalization$427.55 million
P/E RatioN/A
Dividend YieldN/A
Beta1.32
UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing solutions for specialty cancers and urologic diseases. The company's lead product candidates are UGN-101 and UGN-102, which are designed to ablate tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-201, a proprietary immunotherapy product candidate for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was founded in 2004 and is based in Princeton, New Jersey.
UroGen Pharma logo

Headlines

UroGen Pharma Announces March 2021 Conference Schedule
February 23, 2021 |  finance.yahoo.com
UroGen Pharma Ltd. (NASDAQ:URGN): Are Analysts Optimistic?
January 26, 2021 |  finance.yahoo.com
Notable Thursday Option Activity: AAP, URGN, TWLO
November 19, 2020 |  nasdaq.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:URGN
CUSIPN/A
Phone646-768-9780
Employees187
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$20,000.00
Price / Sales21,377.63
Book Value$8.63 per share

Profitability

Net Income$-105,150,000.00

Miscellaneous

Market Cap$427.55 million
Next Earnings DateN/A
OptionableOptionable

MarketRank

Overall MarketRank

1.93 out of 5 stars

Medical Sector

80th out of 1,966 stocks

Pharmaceutical Preparations Industry

31st out of 772 stocks

Analyst Opinion: 3.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -
$20.46
+1.41 (+7.40 %)
(As of 03/1/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive URGN News and Ratings via Email

Sign-up to receive the latest news and ratings for URGN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











UroGen Pharma (NASDAQ:URGN) Frequently Asked Questions

Is UroGen Pharma a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for UroGen Pharma in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" UroGen Pharma stock.
View analyst ratings for UroGen Pharma
or view top-rated stocks.

What stocks does MarketBeat like better than UroGen Pharma?

Wall Street analysts have given UroGen Pharma a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but UroGen Pharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were UroGen Pharma's earnings last quarter?

UroGen Pharma Ltd. (NASDAQ:URGN) released its quarterly earnings results on Monday, November, 9th. The company reported ($1.31) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($1.47) by $0.16. The company had revenue of $3.46 million for the quarter, compared to analysts' expectations of $3.21 million.
View UroGen Pharma's earnings history
.

How has UroGen Pharma's stock price been impacted by COVID-19?

UroGen Pharma's stock was trading at $23.86 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, URGN stock has decreased by 14.2% and is now trading at $20.46.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for URGN?

3 brokerages have issued 1-year price targets for UroGen Pharma's shares. Their forecasts range from $26.00 to $57.00. On average, they anticipate UroGen Pharma's stock price to reach $42.25 in the next year. This suggests a possible upside of 106.5% from the stock's current price.
View analysts' price targets for UroGen Pharma
or view top-rated stocks among Wall Street analysts.

Who are UroGen Pharma's key executives?

UroGen Pharma's management team includes the following people:
  • Ms. Elizabeth A. Barrett, Pres, CEO & Director (Age 59, Pay $1.84M)
  • Dr. Mark P. Schoenberg, Chief Medical Officer (Age 63, Pay $476.6k)
  • Mr. Ron Bentsur, Advisor (Age 55, Pay $699.77k)
  • Ms. Molly Henderson CPA, MBA, Chief Financial Officer (Age 50)
  • Sara Blum Sherman, Sr. Director of Investor Relations
  • Mr. Jason Smith, Gen. Counsel & Chief Compliance Officer
  • Eric Van Zanten, Sr. Director of Communications
  • Dr. Sari Prutchi-Sagiv Ph.D., Marketing Director
  • Dr. Marina Konorty, Exec. VP of R&D and Technical Operations
  • Mr. Jeffrey Bova M.B.A., Chief Commercial Officer

Who are some of UroGen Pharma's key competitors?

What other stocks do shareholders of UroGen Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other UroGen Pharma investors own include Sorrento Therapeutics (SRNE), Micron Technology (MU), OPKO Health (OPK), TG Therapeutics (TGTX), VBI Vaccines (VBIV), Exelixis (EXEL), (KITE) (KITE), Syndax Pharmaceuticals (SNDX), AbbVie (ABBV) and Aytu BioScience (AYTU).

When did UroGen Pharma IPO?

(URGN) raised $46 million in an initial public offering (IPO) on Thursday, May 4th 2017. The company issued 3,500,000 shares at $12.00-$14.00 per share. Jefferies and Cowen and Company served as the underwriters for the IPO and Raymond James and Oppenheimer were co-managers.

What is UroGen Pharma's stock symbol?

UroGen Pharma trades on the NASDAQ under the ticker symbol "URGN."

Who are UroGen Pharma's major shareholders?

UroGen Pharma's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (7.32%), Credit Suisse AG (5.36%), Phoenix Holdings Ltd. (3.92%), Horton Capital Management LLC (1.87%), Northern Trust Corp (1.15%) and Nuveen Asset Management LLC (0.95%). Company insiders that own UroGen Pharma stock include Elizabeth A Barrett, Mark Schoenberg, Peter P Pfreundschuh and Stephen Mullennix.
View institutional ownership trends for UroGen Pharma
.

Which institutional investors are selling UroGen Pharma stock?

URGN stock was sold by a variety of institutional investors in the last quarter, including Phoenix Holdings Ltd., Nuveen Asset Management LLC, JPMorgan Chase & Co., Northern Trust Corp, SG Americas Securities LLC, State of Wisconsin Investment Board, Shikiar Asset Management Inc., and Barclays PLC. Company insiders that have sold UroGen Pharma company stock in the last year include Mark Schoenberg, Peter P Pfreundschuh, and Stephen Mullennix.
View insider buying and selling activity for UroGen Pharma
or view top insider-selling stocks.

Which institutional investors are buying UroGen Pharma stock?

URGN stock was purchased by a variety of institutional investors in the last quarter, including Rice Hall James & Associates LLC, Annandale Capital LLC, Russell Investments Group Ltd., BlackRock Inc., Renaissance Technologies LLC, Bank Hapoalim BM, Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD, and Trexquant Investment LP. Company insiders that have bought UroGen Pharma stock in the last two years include Elizabeth A Barrett, and Mark Schoenberg.
View insider buying and selling activity for UroGen Pharma
or or view top insider-buying stocks.

How do I buy shares of UroGen Pharma?

Shares of URGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is UroGen Pharma's stock price today?

One share of URGN stock can currently be purchased for approximately $20.46.

How much money does UroGen Pharma make?

UroGen Pharma has a market capitalization of $427.55 million and generates $20,000.00 in revenue each year. The company earns $-105,150,000.00 in net income (profit) each year or ($5.12) on an earnings per share basis.

How many employees does UroGen Pharma have?

UroGen Pharma employs 187 workers across the globe.

What is UroGen Pharma's official website?

The official website for UroGen Pharma is www.urogen.com.

Where are UroGen Pharma's headquarters?

UroGen Pharma is headquartered at 400 Alexander Park, Princeton NJ, 08540.

How can I contact UroGen Pharma?

UroGen Pharma's mailing address is 400 Alexander Park, Princeton NJ, 08540. The company can be reached via phone at 646-768-9780 or via email at [email protected]


This page was last updated on 3/2/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.